Waldeir José de Almeida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Waldeir José de Almeida has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Virginia de Assis Silva
Mater Dei Hospital
3 shared publications - Arthur Chaves de Almeida
Universidade Estadual de Campinas (UNICAMP)
2 shared publications - Anna Dias Salvador
Mater Dei Hospital
1 shared publication - Bernardo Bacelar de Faria
Diagnostic Medicine Laboratory-Scapulatempo, Campo Grande 79002-17, Brazil
1 shared publication - Gabriel Oliveira Bernardes Gil
Radiation Oncology; Rede Mater Dei de Saúde; Belo Horizonte Brazil
1 shared publication - Jairo Luis Coelho
Mater Dei Hospital
1 shared publication
Latest Publications
- Open Access
Impact of artificial intelligence on breast care pathways and future perspectives
Artificial intelligence (AI) is a sophisticated technology already established in medicine. In mastology, there is robust evidence of the ability of AI software to optimize screening, reduce interval cancer rates, and decrease patient recall rates. In addition, AI provides parameters for predicting surgical complications and oncological therapeutic outcomes. Considering the rise of AI, this article aimed to conduct an integrative review, highlighting its main tools developed in mastology. A search was performed on the United States National Library of Medicine (PubMed) platform, using descriptors associated with AI and breast cancer. Retrospective studies, systematic reviews, and prospective clinical studies published in English in the last ten years were included. The results were organized by thematic areas and summarized in a table and the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flowchart. Data analysis showed a concentration of information in the area of imaging — with advances in radiomics — and a still incipient, albeit promising, development in areas such as genetics and surgery. The article highlights the need for discussion on the ethical issues surrounding the implementation of AI. The reliability of data collection and manipulation must be guaranteed, and data automation should not imply automation of conduct, since medical responsibility in patient care is perennial.
Open AccessImpact of artificial intelligence on breast care pathways and future perspectives
Artificial intelligence (AI) is a sophisticated technology already established in medicine. In mastology, there is robust evidence of the ability of AI software to optimize screening, reduce interval cancer rates, and decrease patient recall rates. In addition, AI provides parameters for predicting surgical complications and oncological therapeutic outcomes. Considering the rise of AI, this article aimed to conduct an integrative review, highlighting its main tools developed in mastology. A search was performed on the United States National Library of Medicine (PubMed) platform, using descriptors associated with AI and breast cancer. Retrospective studies, systematic reviews, and prospective clinical studies published in English in the last ten years were included. The results were organized by thematic areas and summarized in a table and the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) flowchart. Data analysis showed a concentration of information in the area of imaging — with advances in radiomics — and a still incipient, albeit promising, development in areas such as genetics and surgery. The article highlights the need for discussion on the ethical issues surrounding the implementation of AI. The reliability of data collection and manipulation must be guaranteed, and data automation should not imply automation of conduct, since medical responsibility in patient care is perennial.
- Open Access
Should the use of hormones for contraception and during menopause be contraindicated in women with high-penetrance mutations?
Medical genetics is one of the fields with the greatest advancements in medical knowledge. The discovery of genes that determine greater susceptibility to certain neoplasms has motivated a vast amount aimed at determining the best management of patients with these mutations. The use of hormones, both as contraception and during menopause, for these women is a subject of ongoing debate — given their involvement in the pathophysiology of breast neoplasia. This article, therefore, aims to review the available literature on the topic. Thirteen publications were selected for narrative review. Regarding contraception, individualized assessment of these patients is still paramount in indicating hormonal contraception, with no formal contraindication to its use for patients with high-penetrance mutations. Regarding hormone therapy (HT), there are also no absolute contraindications. Consideration is only given to patients who have not undergone mastectomy. In such cases, HT can be considered for short periods, ideally using micronized progesterone in patients with a uterus.
Open AccessShould the use of hormones for contraception and during menopause be contraindicated in women with high-penetrance mutations?
Medical genetics is one of the fields with the greatest advancements in medical knowledge. The discovery of genes that determine greater susceptibility to certain neoplasms has motivated a vast amount aimed at determining the best management of patients with these mutations. The use of hormones, both as contraception and during menopause, for these women is a subject of ongoing debate — given their involvement in the pathophysiology of breast neoplasia. This article, therefore, aims to review the available literature on the topic. Thirteen publications were selected for narrative review. Regarding contraception, individualized assessment of these patients is still paramount in indicating hormonal contraception, with no formal contraindication to its use for patients with high-penetrance mutations. Regarding hormone therapy (HT), there are also no absolute contraindications. Consideration is only given to patients who have not undergone mastectomy. In such cases, HT can be considered for short periods, ideally using micronized progesterone in patients with a uterus.
- Open Access
Is the use of a dermal matrix mandatory in breast reconstruction with prosthesis after radiotherapy?
Breast reconstruction is a crucial step in the treatment of breast cancer, allowing not only the restoration of body shape but also a significant improvement in patients' quality of life. However, choosing the ideal technique is a multifactorial challenge that requires consideration of several anatomical and clinical aspects. During the Northeast Mastology Conference held in September 2024 in Natal, it was agreed by consensus that the use of a dermal matrix (ADM) is not mandatory in breast reconstruction with prosthesis after radiotherapy.
Open AccessIs the use of a dermal matrix mandatory in breast reconstruction with prosthesis after radiotherapy?
Breast reconstruction is a crucial step in the treatment of breast cancer, allowing not only the restoration of body shape but also a significant improvement in patients' quality of life. However, choosing the ideal technique is a multifactorial challenge that requires consideration of several anatomical and clinical aspects. During the Northeast Mastology Conference held in September 2024 in Natal, it was agreed by consensus that the use of a dermal matrix (ADM) is not mandatory in breast reconstruction with prosthesis after radiotherapy.